



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets,
PRETORIA 0001

Directorate: Access to Affordable Medicines

Tel: (012) 395 8130 Fax: (012) 395 8823/4

Enquiries: CPA Ref:HP12-2020LQe-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP12-2020LQ: SUPPLY AND DELIVERY OF PHARMACEUTICAL LIQUIDS, ALCOHOL, ETHER, GYCERINE AND MENTHYLATED SPIRITS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD OF 01 OCTOBER 2020 TO 30 SEPTEMBER 2023

ADDENDUM 2: ABBOTT LABORATORIES (PTY) LTD – MOQ

Please amend your records for the following Abbott Laboratories (Pty) Ltd MOQ, effective immediately.

Item No	Description	NSN	Current MOQ	Revised MOQ
42	Ibuprofen 100mg/5ml, suspension, 100ml	189712348	57000	120

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Yours faithfully

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
DATE:



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: tenders@health.gov.za

Ref: **HP12-2020LQ**

HP12-2020LQ: SUPPLY AND DELIVERY OF PHARMACEUTICAL LIQUIDS, ALCOHOL, ETHER, GLYCERINE AND METHYLATED SPIRITS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 OCTOBER 2020 TO 30 SEPTEMBER 2023 - VERSION 2

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape	Mr C Dlova	(047) 532-5536	mncedisi.dlova@echealth.gov.za
Free State	Ms M Smits	(051) 411-0525	smitsm@fshealth.gov.za
Gauteng	Mr DS Malele	(011) 628-9131	dumisane.malele@gauteng.gov.za
Kwazulu-Natal	MS SB Nhlapo	(035) 901-7004	sibusisiwe.nhlapo@kznhealth.gov.za
Limpopo	Mr TS Rasekele	(015) 223-9065	rassolly@gmail.com
Mpumalanga	Mr T Moralo	(013) 283-9001	tshegofatsom@mpuhealth.gov.za
North West	Mr M Gutta	(018) 384-4838	mgutta@nwpg.gov.za
Northern Cape	Ms E Delport	(053) 830-2717	edelport@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
For: DIRECTOR-GENERAL: HEALTH
DATE: 9 OCTOBER 2020

1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Abbott Laboratories SA (Pty) Ltd	V2150	MAAA0030395	P O Box 7208 WELTEVREDEN PARK 1715	Maxine Smith	(011) 858-2379 (060) 579-7944	maxine.smith@abbott.com
Adcock Ingram Critical Care (Pty) Ltd	V4222	MAAA0010153	P O Box 6888 JOHANNESBURG 2000	Vusani Matshidza	(011) 494-8129 (079) 894-7873	criticalcare.tenders@adcock.com
Adcock Ingram Healthcare (Pty) Ltd	V2272	MAAA0036413	Private Bag X69 BRYANSTON 2021	Louis Fourie	(011) 635-0671 (083) 735-2007	louis.fourie@adcock.com

**HP12-2020LQ: SUPPLY AND DELIVERY OF PHARMACEUTICAL LIQUIDS, ALCOHOL, ETHER, GLYCERINE AND METHYLATED SPIRITS TO THE DEPARTMENT OF HEALTH
FOR THE PERIOD 01 OCTOBER 2020 TO 30 SEPTEMBER 2023**

VERSION 2

(PAGE 3)

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Barrs Pharmaceuticals Industries (Pty) Ltd	V4890	MAAA0024330	P O Box 7348 ROGGEBAAI 8012	Alfreda Elizabeth Le Roux	(021) 531-6601 (083) 582-1897	alfreda@barrs.co.za
Cipla Medpro South Africa (Pty) Ltd	VXZ32	MAAA0006605	P O Box 32003 MOBENI 4060	Willem Maritz	(011) 315-9150 (082) 887-4926	willem.maritz@cipla.com
Equity Pharmaceuticals (Pty) Ltd	V1QZ3	MAAA0007480	P O Box 60964 PIERRE VAN RYNEVELD 0045	Carel Bouwer	(012) 345-1747 (082) 879-8866	carel@equitypharma.co.za
Gulf Drug Company (Pty) Ltd	VTS03	MAAA0009791	P O Box 754 MOUNT EDGECOMBE 4302	Kevin Moonsamy	(031) 538-8700 (083) 779-1321	kevinm@gulfdrug.co.za
Inova Pharmaceuticals (Pty) Ltd	V2192	MAAA0010561	Private Bag 3115 BEDFORDVIEW 2008	Annamie Rodgers	(011) 087-0000 (083) 991-8847	a.rodgers@inovapharma.com
Maba Africa (Pty) Ltd	To Follow	MAAA0363362	P O Box 36144 MENLO PARK 0102	Nikki Oosthuizen	(087) 073-5770 (083) 376-2472	info@mabafrica.com
Novartis South Africa (Pty) Ltd	VBVW2	MAAA0006317	Novartis Building, Magwa Crescent West Waterfall, Jukskei View MIDRAND 2090	Fareeya Vahed	(011) 347-6600 (083) 997-3131	fareeya.vahed@novartis.com

**HP12-2020LQ: SUPPLY AND DELIVERY OF PHARMACEUTICAL LIQUIDS, ALCOHOL, ETHER, GLYCERINE AND METHYLATED SPIRITS TO THE DEPARTMENT OF HEALTH
FOR THE PERIOD 01 OCTOBER 2020 TO 30 SEPTEMBER 2023**

**VERSION 2
(PAGE 4)**

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Pharmacare Limited	VBKY6	MAAA0008452	P O Box 1593 GALLO MANOR 2052	Itumeleng Mathe	(011) 239-6243 (083) 298-4336	imathe@aspenpharma.com
Resmed Healthcare cc	VCEJ2	MAAA0010098	P O Box 65409 RESERVOIR HILLS 4090	Laljith Sunker Singh	(031) 577-7258 (079) 947-1789	lal@resmed.co.za
Safeline Pharmaceuticals (Pty) Ltd	VZL63	MAAA0002530	P O Box 7900 PALM COURT 1715	David John Frank	(011) 288-5360 (082) 449-4389	davef@safeline.co.za
Sanichem (Pty) Ltd	V2RX2	MAAA0002361	P O Box 28471 MALVERN 4055	Neelan Soobiah Parumaul	(031) 579-3222 (084) 497-5769	neelan@sanichem.co.za
Sanofi-Aventis SA (Pty) Ltd	V2160	MAAA0009069	Private Bag X207 MIDRAND 1685	Jaidev Maharaj	(011) 847-5264 (082) 943-3952	jaidev.maharaj@sanofi.com
Takeda (Pty) Ltd	V6300	MAAA0023041	P O Box 70086 BRYANSTON 2021	Susan Simpson	(011) 514-3000 (082) 681-6319	susan.simpson@takeda.com

Item No	Item Specification	* ADD	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (≤ 14	MOQ	Total Score	National Stock Number	UOM
1	Acetic acid, Glacial BP, 500ml		3 885	3 885	100%	Sanichem (Pty) Ltd	MAAA0002361	V2RX2	Acetic acid, Glacial BP, 500ml	R22.00	1 x 500ml	14	20	90.00	189714840	BT
2	Acetone BP, 500ml		27 284	27 284	100%	Sanichem (Pty) Ltd	MAAA0002361	V2RX2	Acetone BP, 500ml	R25.00	1 x 500ml	14	20	90.00	189714841	BT
3	Acriflavine/Proflavine 0,1% m/v emulsion, 100ml		70 205	70 205	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Acriflavine Emulsion	R16.13	1 x 100ml	14	100	90.00	189713765	BT
4	Alcohol Based hand rubs (Propyl, Isopropyl or Ethanol alcohol or a combination of these) with added emollient, in 500ml bottle with plunger (NOT mist spray) . Minimum standard: WHO I (Ethanol 85%) or WHO II formulation (Isopropyl 75%). EN testing passed for Hygienic Hand Rub (EN1500). SAHPRA registration required		723 500	723 500	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Sterikleen Hand Rub	R15.24	1 x 500ml	14	20	99.00	222001044	EA
5	Alcohol Based hand rubs (Propyl, Isopropyl or Ethanol alcohol or a combination of these) with added emollient, in 50ml bottle with plunger (NOT mist spray) . Minimum standard: WHO I (Ethanol 85%) or WHO II formulation (Isopropyl 75%). EN testing passed for Hygienic Hand Rub (EN1500). SAHPRA registration required		375 690	375 690	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Sterikleen Hand Rub	R5.78	1 x 50ml	14	120	99.00	181861509	BT
6	Aluminium hydroxide BP 300mg/5ml suspension, 500ml		422 151	422 151	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Aluminium Hydroxide Gel B.P.	R20.57	1 x 500ml	14	24	90.00	189714733	BT
7	Benzoin tincture co BP, 100ml		22 644	22 644	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Benzoin Co. Tincture BP	R46.98	1 x 100ml	14	120	99.00	189707410	BT
8	Benzoin tincture co BP, 20ml		89 720	89 720	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Benzoin Co. Tincture BP	R9.88	1 x 20ml	14	384	99.00	189714844	BT
9	Benzyl benzoate 25% emulsion, 100ml		2 013 737	2 013 737	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Benzyl Benzoate Emuls	R3.85	1 x 100ml	14	120	99.00	189707445	BT
10	Calamine lotion BP, 100ml		2 312 172	2 312 172	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Calamine Lotion BP	R4.16	1 x 100ml	14	120	99.43	189703365	BT
11	Carbamazepine 100mg/5ml suspension, 250ml		141 476	141 476	100%	Novartis South Africa (Pty) Ltd	MAAA0006317	VBVW2	Tegretol S	R126.79	1 X 250ml	7	1	91.00	189712347	BT
13	Cetirizine 5mg/5ml syrup, 150ml		472 392	472 392	100%	Cipla Medpro South Africa (Pty) Ltd	MAAA0006605	VXZ32	Allecet Syrup	R10.91	1 x 150ml bottle	14	60	96.00	181894020	BT
14	Chlorhexidine 0.2% mouthwash solution, 200ml		1 626 332	1 626 332	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Chlorhexidine Gluconate 0.2% mouthwash	R6.45	1 x 200ml	14	50	90.00	189714848	BT
15	Chlorhexidine 0.5% in Alcohol 70% solution without emollient, 500ml Coloured red. Compliance certificate to be included. SAHPRA registration required		1 709 780	1 709 780	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Steriprep	R13.56	1 x 500ml	14	20	99.00	180090749	BT

Item No	Item Specification	* ADD	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (≤ 14	MOQ	Total Score	National Stock Number	UOM
16	Chlorhexidine 4% solution, surgical scrub, 500ml bottle supplied with pump. Compliance certificate to be included.		3 569 668	3 569 668	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Steriscrub	R22.87	1 x 500ml	14	20	99.00	189705153	BT
17	Chlorhexidine gluconate and Benzylamine, 22.5mg and 18mg /15ml mouthwash solution, 200ml		467 890	467 890	100%	Inova Pharmaceuticals (Pty) Ltd	MAAA0010561	V2192	Andolex-C Oral Rinse 200ml	R46.44	1 x 200ml	14	1	90.00	180257846	BT
20	Chlorphenamine 2mg/5ml syrup, 50ml		17 218 078	15 496 270	90%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Histagex	R3.40	1 x 50ml	14	100	90.00	189711414	BT
				1 721 808	10%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Allergex Syrup 50ml	R5.00	1 x 50ml	14	1 shipper	57.65		
22	Coal tar solution BP, 500ml		22 431	22 431	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Coal Tar Solution B.P.	R52.30	1 x 500ml	14	6	90.00	189712370	BT
25	Enzymatic cleaner for surgical instruments containing amylase and protease enzymes. Multi-purpose pre-soak and cleaner for manual and automated cleaning and ultrasonic washers. Suitable for endoscopes. Neutral pH. Able to remove all organic soil and debris containing protein, lipids and starches. Concentrate, use dilution to be stated. 2.5 - 5 L. Must be registered with the National Regulator for Compulsory Specification (NRCS)- compliance certificate to be included and manufacture's ISO 9001 Certificate		7 050	7 050	100%	Maba Africa (Pty) Ltd	MAAA0363362	VHGU5	Pristine	R136.09	1 x 5L	7	4	90.00	181919462	CO
26	Enzymatic cleaner for surgical instruments containing amylase, lipase and protease enzymes. endoscopes. Neutral pH. Concentrate, use dilution to be stated. 2.5 - 5 L. Must be registered with the National Regulator for Compulsory Specification (NRCS)- compliance certificate and ISO 9001 Certificate to be included		16 320	16 320	100%	Maba Africa (Pty) Ltd	MAAA0363362	VHGU5	Pristine	R136.09	1 x 5L	7	4	90.00	180970906	CO
27	Ergocalciferol 5000IU/ml solution, 15ml		248 690	248 690	100%	Pharmacare Limited	MAAA0008452	VBKY6	Calciferol Solution 15ml	R61.76	1 x 15ml	14	6	95.00	189712409	BT
28	Ethanol 70% surface disinfectant 500ml pour bottle. Must comply with latest version of SANS 490. Compliance certificate to be included. SAHPRA registration required		77 440	77 440	100%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ADCO ALCOHOL TYPE 1 SURFACE DISINFECTANT 500ML	R67.16	1 x 500ml	14	20	100.00	181897182	BT
31	Ferrous gluconate 350mg/5ml, equivalent to elemental iron 40mg/5ml, syrup, 100ml		1 186 060	1 186 060	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Ferrous Glucoate Syrup	R6.57	1 x 100ml	14	100	90.00	180079580	BT
33	Formaldehyde solution BP, 1L		9 354	9 354	100%	Sanichem (Pty) Ltd	MAAA0002361	V2RX2	Sani-Formaldehyde	R29.00	1 x 1L	14	20	90.00	189700822	LI
34	Furosemide 10mg/ml solution, 100ml		50 070	50 070	100%	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	LASIX ORAL SOLUTION	R242.89	1 x 100ml	14	75	90.00	189714763	BT
35	Glutaraldehyde 2% solution, not in concentrated form. Stability after opening or activating must be at least 14 days, 1 litre. Must comply with latest version of SANS1615 - compliance certificate to be included		70 960	70 960	100%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ENDOSCOPE HIGH LEVEL DISINFECTANT TYPE 1 ADCO 1000ML	R40.25	1 x 1000ml	14	10	100.00	189705449	LI

Item No	Item Specification	* ADD	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (≤ 14	MOQ	Total Score	National Stock Number	UOM
36	Glutaraldehyde 2% solution, not in concentrated form. Stability after opening or activating must be at least 14 days, 5L. Must comply with latest version of SANS 1615 - compliance certificate to be included		7 850	7 850	100%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ENDOSCOPE HIGH LEVEL DISINFECTANT TYPE 1 ADCO 5000ML	R163.30	1 x 5000ml	14	4	100.00	180181171	CO
37	Glycerol BP, 500ml		10 726	10 726	100%	Sanichem (Pty) Ltd	MAAA0002361	V2RX2	Refined Glycerine 500ml	R22.00	1 x 500ml	14	20	90.00	189715124	BT
38	Glyco-Thymol Compound, mouthwash, 100ml		1 405 952	1 405 952	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Compound Thymol Glycerine	R2.93	1 x 100ml	14	100	90.61	189712406	BT
39	Halothane liquid, 250ml		1 485	1 485	100%	Safeline Pharmaceuticals (Pty) Ltd	MAAA0002530	VZL63	HALOTHANE	R423.52	1 x 250ml	14	144	90.00	189750285	BT
40	Hydrogen peroxide BP, 6% solution, 500ml		53 580	53 580	100%	Sanichem (Pty) Ltd	MAAA0002361	V2RX2	Hydrogen peroxide BP, 6% Solution 500ml	R8.50	1 x 500ml	14	20	90.00	189700824	BT
41	Hyoscine-N-Butylbromide 5mg/5ml syrup, 100ml		128 188	128 188	100%	Pharmacare Limited	MAAA0008452	VBKY6	Hyospasmol Syrup 100ml	R19.84	1 x 100ml	14	12	95.00	180074004	BT
42	Ibuprofen 100mg/5ml, suspension, 100ml	2	2 373 774	2 373 774	100%	Abbott Laboratories SA (Pty) Ltd	MAAA0030395	V2150	Brufen for children	R16.91	1 x 100ml	14	57000 120	91.00	189712348	BT
45	Isoflurane liquid, 250ml		36 835	36 835	100%	Safeline Pharmaceuticals (Pty) Ltd	MAAA0002530	VZL63	ISOFOR	R358.82	1 x 250ml	14	144	90.00	180199767	BT
46	Lactulose 3.3g/5ml, syrup, 150ml		2 736 910	2 736 910	100%	Pharmacare Limited	MAAA0008452	VBKY6	Lacson Syrup 150ml	R31.14	1 x 150ml	14	24	92.35	189707998	BT
47	Lactulose 3.3g/5ml, syrup, 500ml		152 320	152 320	100%	Pharmacare Limited	MAAA0008452	VBKY6	Lacson Syrup 500ml	R90.28	1 x 500ml	14	20	95.00	189711239	BT
48	Liquid paraffin BP, 200ml		1 006 186	1 006 186	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Liquid Paraffin BP	R8.35	1 x 200ml	14	70	99.32	189714770	BT
49	Lubricant and cleaner for surgical instruments, compatible with stainless steel, titanium, tungsten carbide and aluminium. neutral pH. Concentrate, use dilution to be stated. 2.5 - 5 L. To submit: manufacturer's ISO 9001 certificate		12 430	12 430	100%	Sanichem (Pty) Ltd	MAAA0002361	V2RX2	SaniGlide	R230.00	1 x 3.8L	14	20	90.00	180162159	CO
51	Methadone 2mg/ml solution, 60ml		4 552	4 552	100%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Equity Methadone	R56.50	1 x 60ml	14	12	91.00	222000194	BT
52	Metoclopramide 5mg/5ml syrup, 50ml		395 470	395 470	100%	Pharmacare Limited	MAAA0008452	VBKY6	Clopamon 5mg Syrup 100ml	R24.78	1 x 100ml	14	12	95.00	189707039	BT
53	Paracetamol 120mg/5ml, syrup, alcohol, sugar and tartrazine free, 100ml		13 906 662	13 906 662	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Paracetamol Syrup	R3.85	1 x 100ml	14	120	99.00	181783743	BT
54	Paracetamol 120mg/5ml, syrup, alcohol, sugar and tartrazine free, 500ml		204 560	204 560	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Paracetamol Syrup	R15.79	1 x 500ml	14	30	99.00	181783747	BT
55	Paracetamol 120mg/5ml, syrup, alcohol, sugar and tartrazine free, 50ml		13 705 374	13 705 374	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Barrs Paracetamol Syrup	R2.47	1 x 50ml	14	150	99.00	189712404	BT

Item No	Item Specification	* ADD	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (≤ 14	MOQ	Total Score	National Stock Number	UOM
56	Phenobarbitone 16mg/5ml syrup, 100ml		33 887	33 887	100%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Phenobarb Elixir 100ml	R36.23	1 x 100ml	14	1 Shipper	100.00	189708072	BT
58	Pholcodine 15mg/5ml linctus, 100ml		88 900	88 900	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Pholcodine Linctus	R29.00	1 x 100ml	14	100	90.00	181828236	BT
59	Potassium citrate mixture 1.5g/5ml, 200ml		147 150	147 150	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Potassium citrate mixture 30%	R10.86	1 x 200ml	14	50	90.00	189705099	BT
60	Povidone iodine 100mg/ml, solution, 100ml		91 704	91 704	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Peviderm	R7.32	1 x 100ml	14	120	99.00	181861436	BT
61	Povidone iodine 100mg/ml, solution, 1L		604 007	604 007	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Peviderm	R57.88	1 x 1000ml	14	12	99.00	189712302	BT
64	Promethazine 5mg/5ml syrup, 100ml		67 290	67 290	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Triomethazine Elixir	R7.52	1 x 100ml	14	100	90.00	189702847	BT
65	Propylene glycol BP, 2.5 litre		875	875	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Propylene Glycol	R199.27	1 x 2.5L	14	5	90.00	189714878	CO
67	Rust and stain remover for surgical instruments For the removal of water mineral staining, rust and corrosion from stainless steel surgical instruments, trays and basins. Non-corrosive. Concentrate, Use dilution to be stated. 2.5 - 5 L To submit: manufacturer's ISO 9001 certificate, 93/42/EEC medical device directive		1 440	1 440	100%	Maba Africa (Pty) Ltd	MAAA0363362	VHGU5	Pristine	R172.89	1 x 5L	7	4	90.00	180199137	CO
68	Sevoflurane liquid, 250ml		97 650	97 650	100%	Safeline Pharmaceuticals (Pty) Ltd	MAAA0002530	VZL63	SOJOURN	R813.46	1 x 250ml	14	72	90.00	180190323	CO
69	Sodium phosphate and Sodium acid phosphate 60mg and 160 mg/ml enema solution, 135ml - 150ml		671 860	671 860	100%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ADCO FOSENEA 150ML	R17.19	1 x 150ml	14	10	100.00	189712241	BT
70	Sorbitol 70% solution, 500ml		13 992	13 992	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Sorbitol 70%	R61.98	1 x 500ml	14	24	90.00	222001045	EA
71	Syrup simplex BP, 2.5L		3 665	3 665	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Syrup Simplex BP	R73.10	1 x 2.5L	14	5	90.00	181777984	CO
73	Valproic acid 200mg/5ml liquid, 300ml		781 408	781 408	100%	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM LIQUID 300ML	R138.79	1 x 300ml	14	24	90.00	189709032	BT
74	Valproic acid 250mg/5ml liquid, 100ml		17 120	17 120	100%	Takeda (Pty) Ltd	MAAA0023041	V6300	Convulex Syrup	R99.67	1 x 100ml	7	10	90.00	189713767	BT
75	Vitamin, Multiple oral drops, containing per 0,6ml: Vit. A 3000 - 5000iu, Nicotinamide 10mg, Vit. D 400 iu, Vit. B1 (Thiamine) 1,5mg, Vit. B2 (Riboflavine) 1,2mg, Vit. B6 (Pyridoxine) 0,5 mg, Vit. C 50mg, 25ml, boxed with calibrated dropper		823 411	823 411	100%	Barrs Pharmaceuticals Industries (Pty) Ltd	MAAA0024330	V4890	Kiddyvit	R9.34	1 x 25ml	14	50	99.38	189700483	BT

Item No	Item Specification	* ADD	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead- Time (≤ 14	MOQ	Total Score	National Stock Number	UOM
76	Vitamin, Multiple syrup, containing per 5ml: Vit. A 3000 iu, Vit. D 400 iu, Vit. B1 (Thiamine) 1.5mg, Vit. B2 (Riboflavine) 1.25mg, Vit. B6 (Pyridoxine) 1mg, Vit. C 50mg, Nicotinamide 10mg, 100ml		8 970 820	6 000 000	67%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Gulf Multivitamin Syrup	R3.92	1 x 100ml	14	150	94.00	189718286	BT
77	Zinc, equivalent to elemental zinc 10mg/5ml, syrup, 150ml		2 432 650	2 432 650	100%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Resmed Elemental Zinc Syrup	R3.98	1 x 150ml	14	80	90.00	181919467	BT



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP12-2020LIQ

**SUPPLY AND DELIVERY OF PHARMACEUTICAL LIQUIDS, ALCOHOL, ETHER,
GYCERINE AND MENTHYLATED SPIRITS TO THE DEPARTMENT OF HEALTH FOR THE
PERIOD FROM 01 OCTOBER 2020 TO 30 SEPTEMBER 2023**

BID VALIDITY PERIOD: 120 DAYS

CLOSING DATE AND TIME OF BID:

9 MARCH 2020 AT 11:00



TABLE OF CONTENTS

ABBREVIATIONS	3
BID DOCUMENT CHECK LIST	4
SECTION A	7
1. LEGISLATIVE AND REGULATORY FRAMEWORK	7
2. BID INFORMATION SESSION	7
3. EVALUATION CRITERIA	7
3.2 PHASE II: MANDATORY REQUIREMENTS	8
3.2.1 LEGISLATIVE REQUIREMENTS TO THIS BID	8
3.2.2 RESPONSIVE BIDS	9
3.2.3 BID RESPONSE DOCUMENT	9
3.2.4 AUTHORISATION DECLARATION	9
3.2.5 TAX COMPLIANCE STATUS	10
4. PHASE III: PRODUCT TECHNICAL COMPLIANCE	11
4.2 COMPLIANCE WITH SPECIFICATIONS	12
5. PHASE IV: PREFERENCE POINT SYSTEM	12
6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS	13
SECTION B	19
7. VALUE ADDED TAX	14
8. SUBMISSION OF BIDS	14
9. COMPLETION OF DOCUMENTS AND BID SUBMISSION	16
10. LATE BIDS	17
SECTION C	27
11. COUNTER CONDITIONS	17
12. FRONTING	17
13. SUPPLIER DUE DILIGENCE	18
14. COMMUNICATION	18
29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS	33
15. CONTACT DETAILS	18
16. CONTRACT PERIOD	19
17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENT	19
18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES	19
19. POST AWARD PARTICIPATION	20
20. AWARD CONDITIONS	20
20.1. SPLIT AND MULTIPLE AWARDS	21
21. NEGOTIATIONS	22
22. NON-COMMITMENT	22
23. PRICE REVIEW	22
24. QUALITY	26
25. DELIVERY AND QUANTITIES	26
26. SUPPLIER PERFORMANCE MANAGEMENT	27
27. PACKAGING, LABELLING AND BARCODES	30
28. SHELF LIFE	32
28. THIRD PARTIES	33



ABBREVIATIONS

API	: Active Pharmaceutical Ingredient
BAC	: Bid Adjudication Committee
B-BBEE	: Broad-Based Black Economic Empowerment
CPA	: Contract Price Adjustment
CSD	: Central Supplier Database
EAN	: European Article Numbering
EME	: Exempted Micro Enterprise
GMP	: Good Manufacturing Practice
MCC	: Medicines Control Council
MHPL	: Master Health Products List
MPC	: Master Procurement Catalogue
NDoH	: National Department of Health
PPPFA	: Preferential Procurement Policy Framework Act
QSE	: Qualifying Small Enterprise
RoE	: Rate of Exchange
SAHPRA	: South African Health Products Regulatory Authority
SARS	: South African Revenue Service
SBD	: Standard Bidding Document
VAT	: Value- Added Tax



BID DOCUMENT CHECK LIST

All bid documents listed below must be sorted, filed and submitted in the **exact** compilation sequence as indicated below and the annexure attached.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
1	CL	Covering Letter				
2	BSRA	Bid Signature. Resolution/Authority to sign bid				
3	BFI	Bid/File Index				
4	PBD4.1	PBD 4.1: Contact Details of Bidder				
5	SBD5.1	SBD 1: Invitation to bid				
6	TCC	Tax Clearance Certificate (Current & Valid)				
7	CSD	CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted.				
8	SBD4	SBD 4: Declaration of interest				
9	PBD9	PBD9: Directors: Categorisation by race, gender and disability				
10	SBD5	SBD5: The National Industrial Participation Programme				
11	SBD6	SBD 6(1): Preference Points Claimed (B-BBEE)				
12	BBBEE	Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points				



Special Requirements and Conditions of Contract: HP12

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
13	SBD8	SBD 8: Declaration of Past SCM Practices				
14	SBD9	SBD 9: Certificate of Independent Bid Determination				
15	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may will invalidate the bid.				
16	PBD1.1	PBD 1.1: List of products offered sourced from third party				
17	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party.				
18	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.				
19	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.				
20	CIPC	CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates				
21	NC	Proof of company cedings, mergers and name changes				
22	LICMI	Licence to manufacture or import (in the name of the bidder), including all annexures. Certified copies required.				
23	MRC	Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.				



Special Requirements and Conditions of Contract: HP12

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
24	PI	Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order.				
25	BL	Bidder's item list (List of products offered)				
26	PRICE	Signed Excel Bid Response Pricing Schedule				
All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above						
Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column						

The bid document check list is available as **Annexure A** in an excel spreadsheet format and should be completed by all bidders and be submitted in hard copy and as part of the electronic copies of **"Set 3: Electronic version of bid documents"**



SECTION A

1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract (SRCC) are supplementary to General Conditions of Contract (GCC). Where, however, the SRCC are in conflict with the GCC, the SRCC prevail.

2. BID INFORMATION SESSION

- A non - compulsory information session will be held on:

Date: 20 February 2020

Time: 11 AM

Venue: Department of National Health, Impilo Conference Room, Podium Level, Civitas Building, cnr. Thabo Sehume and Struben Streets, PRETORIA, 0002

- It is **strongly recommended** that all prospective bidders attend the information session, which will provide bidders with an opportunity to obtain clarity on the bidding process, the conditions of contract and obtain clarity on any questions that may arise.

3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

Phase I	Phase II	Phase III	Phase IV
Mandatory and other bid requirements	Product technical compliance	Price and B-BBEE	Recommendation and Award



Compliance with mandatory and other bid requirements	Compliance with technical specifications Test reports received from sample evaluation	Bids evaluated in terms of the 90/10 preference system	Recommendation and award
--	--	--	--------------------------

3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1)(b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of such licence must be submitted by the bidder offering the product.

A certified copy of the Medicine Registration Certificate, issued in terms of section 15(3)(a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures, must be included with the bid for all items offered.

Where an item offered is not registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), a package insert of the item must be provided. Where there is no PI available, a legible copy of the label must be provided.



Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.

3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The excel bid response documents i.e pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof. All pages must be signed, if not your bid will not be considered for evaluation.

The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery.

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.

Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.



3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.

In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.

Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration and, should the information be found to be false or incorrect, the National Department of Health will exercise any of the remedies available to it in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, will invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

3.1.5 TAX COMPLIANCE STATUS

The validity of the Tax Clearance Certificate issued by the South African Revenue Services (SARS) certifying that the tax status of the bidder is in order, will be verified against the information recorded in the Central Supplier Database (CSD).

It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.



Bidders are required to be registered on the CSD managed by National Treasury. The National Department of Health shall verify the bidder's tax compliance status through the CSD. Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database. Bidders remain responsible to update their CSD information in line with the bid documents submitted for this bid.

4. PHASE II: PRODUCT TECHNICAL COMPLIANCE

4.1 SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with products to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health entities listed below will invalidate the bid for such items offered.

Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:

Mr Dumisani Malele Depot Manager Tel: 011 628 9131 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001
--	---

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.



- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above. Proof of sample submission must be submitted with the bid documents at the closing date and time of the bid.
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.
- All samples submitted must include the package insert or document detailing professional information approved by the MCC or SAHPRA.

4.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.

5. PHASE III: PREFERENCE POINT SYSTEM

5.1 A MAXIMUM OF 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

$$P_s = 90 \times \left(1 - \frac{P_t - P_{\min}}{P_{\min}} \right)$$

Where:

P_s = Points scored for comparative price of bid under consideration

P_t = Comparative price of bid under consideration

P_{\min} = Comparative price of lowest acceptable bid

5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
1	10	20



B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
2	9	18
3	6	14
4	5	12
5	4	8
6	3	6
7	2	4
8	1	2
Non-compliant contributor	0	0

For this tender, the 90/10 preference point system will be applied.

- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of B-BBEE status level verification certificate, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.
- Only bidders who have completed and signed the declaration part of the preference claim form and who have submitted a B-BBEE status level certificate issued by a registered auditor, accounting officer (as contemplated in section 60(4) of the Close Corporation Act, 1984 (Act No. 69 of 1984)) or an accredited verification agency will be considered for preference points.
- If the bidder fails to comply with the paragraphs above, the bidder will be deemed not to have claimed preference points for B-BBEE status level of contribution and will therefore be allocated a zero (0). The National Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it has made with regard to preference claimed. The points scored will be rounded off to the nearest two (2) decimals. In the event that two (2) or more bids have scored equal total points, the contract will be awarded to the bidder scoring the highest number of preference points for B-BBEE.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.



6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured.

In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture pharmaceutical liquids, alcohol, ether, glycerine and menthylated spirits (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.

Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not **negatively impact upon security of supply and affordability**.

Bids for products that qualify for this preference must comply with all of the following criteria:

- The South African Health Product Authority (SAHPRA) certificate of registration for a product lists the primary site of production as one that is located in the Republic of South Africa;
- The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1)(b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of such licence must be submitted by the bidder offering the product;
- The bidder offering a product must submit a **certified copy** of the licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant;
- The reference price as published by National Department of Health has not been exceeded (if applicable);
- The site/s of manufacture and/or packaging for the product offered is located in South Africa;
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance; and
- Compliance to all other aspects contained in these Special Requirements and Conditions of Contract

7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.



8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the **exact** compilation sequence as indicated below and the annexure attached.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter;
 - Bid Signature. Resolution/Authority to sign bid;
 - Bid/File Index (compilation sequence);
 - PBD 4.1: Contact Details of Bidder;
 - SBD 1: Invitation to bid;
 - Tax Clearance Certificate (Current & Valid);
 - VAT Certificate (Current & Valid);
 - CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
 - SBD 4: Declaration of interest;
 - PBD9: Directors: Categorisation by race, gender and disability;
 - SBD5: The National Industrial Participation Programme;
 - SBD 6(1): Preference Points Claimed (B-BBEE);
 - Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
 - SBD 8: Declaration of Past SCM Practices;
 - SBD 9: Certificate of Independent Bid Determination;
 - PBD1: Authorisation Declaration;
- Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;



- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers and name changes;
- Licence to manufacture or import (in the name of the bidder), **including all annexures**. Certified copies required;
- Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies
Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order;
- Bidder's item list (List of products offered);
- Signed Excel Bid Response Pricing Schedule; and
- Bid Document Check List.

9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 and submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

Set 1: Hard copy legally binding bid documents

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.



Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages. All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

10. LATE BIDS

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, will be returned unopened to the bidder.

11. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

12. FRONTING

The National Department of Health supports the spirit of broad based black economic empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting



themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.

13. SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due diligence prior to final award and / or at any time during the contract period. This may include site visits to assess whether

- an item is manufactured at the site specified in the bid documentation;
- there is compliance with the details provided in the MRC (where applicable);
- the bidder/contracted supplier has two (2) months buffer stock on hand;
- the bidder/contracted supplier has capacity for their allocation or agreed demand.

14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary.

All communication between the bidder and the National Department of Health, must be done in writing to tenders@health.gov.za

Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged. In cases where it is necessary, communication must be in writing to tenders@health.gov.za



15. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines

Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines

Civitas Building

242 Struben Street

Cnr Thabo Sehume Street

Pretoria

0002

Please use the following e-mail address for any queries relating to bidding process:

- tenders@health.gov.za



SECTION B

16. CONTRACT PERIOD

The contract shall be for the period from 1 October 2020 to 30 September 2023.

17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are:

National Departments:

- Department of Correctional Services;
- Department of Defence

Provincial Departments:

- | | |
|------------------|---------------------|
| • Eastern Cape; | • Mpumalanga; |
| • Free State; | • Northern Cape; |
| • Gauteng; | • North West; |
| • KwaZulu-Natal; | • Western Cape; and |
| • Limpopo. | |

Other Institutions

- Nelson Mandela Children's Hospital

18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in inability to process payment for goods.



19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.

The National Department of Health reserves the right to negotiate prices.

The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The following are examples of considerations which may be taken into account when contemplating a multiple award:

- Source of Active Pharmaceutical Ingredient (API) and actual manufacturing site;
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.

In cases where the tender does not achieve the most economically advantageous price, the National Department of Health reserves the right not to award that item.

The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand.



The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.

20.1 SPLIT AND MULTIPLE AWARDS

Two-way split awards will be made in accordance with the following schedule based on the points scored:

Category	Difference between points scored	Recommended percentage split
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10

Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score - mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%

21 NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full.

The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award.

In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.



23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the international market place.

23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on:

- The submission of a complete price breakdown per instructions below for all relevant products; and
- Assessment of the rationality of this price breakdown by the National Department of Health.

23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components
 - Active Pharmaceutical Ingredients (API);
 - Formulation;
 - Packaging;
 - Logistics (this includes transportation, warehousing and distribution);
 - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).



- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE.

Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

Currency	Base Average Rates of Exchange Average for the period 1 July 2019 to 31 December 2019
Rand per US Dollar	14.70
Rand per Br Pound	18.49
Rand per Euro	16.31
Rand per Danish Krone	2.18
Rand per Yuan Renminbi	2.09
Rand per Indian Rupee	0.21

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period **1 July 2019 to 31 December 2019** using the South African Reserve Bank published rates for the specific currency.



23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.

23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 October 2020 - 31 March 2021	02 April 2021	03 May 2021
2	01 April 2021 - 30 September 2021	02 October 2021	02 November 2021
3	01 October 2021 - 31 March 2022	04 April 2022	02 May 2022
4	01 April 2022 - 30 September 2022	03 October 2022	01 November 2022
5	01 October 2022 - 31 March 2023	03 April 2023	01 May 2023

23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
0.1	01 October 2020 - 31 December 2020	04 January 2021	01 February 2021
1.1	01 April 2021 - 31 June 2021	02 July 2021	02 August 2021
2.1	01 October 2021 - 31 December 2021	03 January 2022	01 February 2022



Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
3.1	01 April 2022 - 31 June 2022	04 July 2022	01 August 2022
2.1	01 October 2022 - 31 December 2022	03 January 2023	01 February 2023
3.1	01 April 2023 - 31 June 2023	03 July 2023	01 August 2023

Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:

Review	Period for calculating adjustment average RoE post exceptional adjustment	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 January 2020 - 31 March 2021	02 April 2021	03 May 2021
2	01 July 2021 - 30 September 2021	02 October 2021	02 November 2021
3	01 January 2021 - 31 March 2022	04 April 2022	02 May 2022
4	01 July 2022 - 30 September 2022	03 October 2022	01 November 2022
5	01 January 2022 - 31 March 2023	03 April 2023	01 May 2023

23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.

Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.



24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.

25. DELIVERY AND QUANTITIES

25.1 DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.

Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time will result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

25.2 QUANTITIES

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period. Fluctuations in monthly demand may occur.

Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.



SECTION C

26. SUPPLIER PERFORMANCE MANAGEMENT

26.1 Supplier performance management will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, National Treasury: Transversal Contracting Chief Directorate and National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
 - All transactional data relating to orders;
 - A monthly age analysis;
 - Production pipeline data and forecast including:
 - Number of units of the item available (stock on hand);
 - Number of units of the item in Quality Assurance, awaiting release;
 - Number of units of the item in the current and following two (2) months' production plan.
 - Status of outstanding orders (including status of lead time).
- **Attendance of compulsory quarterly meetings**
 - The National Department of Health will hold quarterly meetings / teleconferences with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter.
 - Attendance of quarterly meetings is compulsory for all invited suppliers
 - Contracted Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.
- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.



- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.
- Contracted Suppliers should note that each individual purchasing institution is responsible for generating the purchase order(s) as well as for the payment(s) thereof.
- Contracted Suppliers should note that the purchase order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s). Only orders using an official, authorised purchase order format are valid.
- The instructions appearing on the official purchase order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
- Contracted Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
- The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
- In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
- In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.
- Invoices must reflect both the "proprietary name" (brand name/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related



Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.

- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery point. These documents must be delivered to the authority responsible for payment. This may or may not be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where documents must be delivered.
- The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
- Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
- Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contracted Suppliers must maintain sufficient buffer stock throughout the duration of the contract.
- Contracted Suppliers must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
 - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
 - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
 - industrial action
 - challenges with manufacturing pipeline;
 - any other supply challenges.
- Contracted Suppliers must direct official communication relating to continuity of supply to stockalert@health.gov.za, as well as Participating Authorities.
- Contracted Suppliers must direct official communication relating to payment challenges to medacc@health.gov.za, as well as Participating Authorities.



- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.
- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier will source alternative product of acceptable quality and up to the same quantity as required in terms of the contract. The substitute item will be supplied at the current price of the contracted item.
- Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
- In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

27. PACKAGING, LABELLING AND BARCODES

27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.



- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
 - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
 - Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
 - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;.
 - The outer packaging must be clearly marked as a "Part Box".

27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC.
 - Registered product name (if applicable);
 - Number of units in pack;
 - Batch number;
 - Expiry date;
 - Storage conditions;
 - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.



- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL) which will replace the MPC.
 - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
 - Dosage form and strength;
 - Pack size;
 - Batch number;
 - Expiry date.

28 SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
 - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
 - Applications are approved by the Participating Authorities before execution of orders; and
 - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
 - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:



- $A = (12 - \text{months to date of expiry}) \times 2\% \times \text{consignment value short dated product}$. Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

The National Department of Health reserves the right to agree to the transfer of contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.

A contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

30. THIRD PARTIES

Participating Authorities will not make a payment to or consult with a third party.

No third party is entitled to put an account of a Participating Authority on hold.

END